Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback